Last reviewed 2026-04-22 · How we verify

AC-170 0.24%

Aciex Therapeutics, Inc. · Phase 3 active Small molecule

AC-170 0.24% is a Small molecule drug developed by Aciex Therapeutics, Inc.. It is currently in Phase 3 development for Glaucoma, Ocular hypertension.

AC-170 is a topical ophthalmic agent that reduces intraocular pressure, likely through enhanced aqueous humor outflow or reduced production.

AC-170 is a topical ophthalmic agent that reduces intraocular pressure, likely through enhanced aqueous humor outflow or reduced production. Used for Glaucoma, Ocular hypertension.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AC-170 0.24%
Sponsor	Aciex Therapeutics, Inc.
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	Phase 3

Mechanism of action

AC-170 is being developed as a novel therapeutic for glaucoma and ocular hypertension. The exact molecular mechanism is not publicly disclosed in detail, but the 0.24% formulation suggests a topical eye drop preparation designed to lower intraocular pressure through modulation of aqueous humor dynamics. Phase 3 development indicates clinical efficacy has been demonstrated in earlier trials.

Approved indications

Glaucoma
Ocular hypertension

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AC-170 0.24% CI brief — competitive landscape report
AC-170 0.24% updates RSS · CI watch RSS
Aciex Therapeutics, Inc. portfolio CI

Frequently asked questions about AC-170 0.24%

What is AC-170 0.24%?

AC-170 0.24% is a Small molecule drug developed by Aciex Therapeutics, Inc., indicated for Glaucoma, Ocular hypertension.

How does AC-170 0.24% work?

AC-170 is a topical ophthalmic agent that reduces intraocular pressure, likely through enhanced aqueous humor outflow or reduced production.

What is AC-170 0.24% used for?

AC-170 0.24% is indicated for Glaucoma, Ocular hypertension.

Who makes AC-170 0.24%?

AC-170 0.24% is developed by Aciex Therapeutics, Inc. (see full Aciex Therapeutics, Inc. pipeline at /company/aciex-therapeutics-inc).

What development phase is AC-170 0.24% in?

AC-170 0.24% is in Phase 3.

Manufacturer: Aciex Therapeutics, Inc. — full pipeline
Therapeutic area: All drugs in Ophthalmology
Indication: Drugs for Glaucoma
Indication: Drugs for Ocular hypertension

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing